fits in terms of reduced storage and administration costs. [1] [2] [3] [4] Diphtheriatetanus-pertussis vaccines have been in use since the 1940s and have become the cornerstone for vaccination of infants worldwide. The acellular pertussis components were recently developed to reduce the severity of adverse events commonly associated with the older whole cell components. 5, 6 Many countries have now adopted the use of acellular pertussis-containing DTaP vaccines, since their clinical efficacy was successfully demonstrated between 1994 to 1996. 6 In recent years vaccination against Haemophilus influenzae type b and also against hepatitis B have been introduced into many vaccination programs. Furthermore, an increasing number of countries now recommend the use of inactivated polio virus vaccines rather than oral polio virus vaccines because of the small risk for vaccineassociated paralytic poliomyelitis associated with the latter. To meet these demands, a number of different DTaP combination vaccines with the previously described antigens have been licensed in many countries or are now in the final stages of development. 7 The combination of HBV and IPV with DTaP has had no effect on the immune response of the individual components; however, there has been a consistent pattern of diminished anti-PRP antibody concentrations after Hib is combined with DTaP or DTaPbased combinations. [8] [9] [10] [11] These results raise concerns over the possible negative impact on the effectiveness of these vaccines against invasive Hib disease. However, several DTaP-based Hib combinations have subsequently been licensed, 2 of which, DTaP/Hib and DTaP-IPV/Hib, have been in wide use in Germany since 1996. Surveillance data from Germany suggest that such combinations offer an excellent protection against Hib disease. 12 Furthermore, the level of antibody is unlikely to be solely responsible for affording protection, and other factors such as immune memory and specific functional activities, which are less markedly affected by combination with DTaP, are also thought to play an important role. 13 This trial was a feasibility study designed to investigate 2 means of administering diphtheria, tetanus, acellular pertussis, hepatitis B, IPV, and Hib vaccines as a primary vaccination course in infancy. The first 5 components have been combined to give a candidate DTaP-HBV-IPV vaccine. The aim of the trial was to compare the immunogenicity and reactogenicity of DTaP-HBV-IPV and Hib vaccines administered separately and in combination.
METHODS

Design and Subjects
This was an open, randomized, multicenter study conducted at the Department of Pediatrics, ChristianAlbrechts-Universität zu Kiel and 12 private pediatric offices in the same locality. Parents provided written informed consent for the study, which had received approval by the appropriate Ethical Review Boards and was conducted according to the guidelines of the Declaration of Helsinki, Good Clinical Practice, and the German Drug Act.
A total of 359 healthy infants between the age of 8 and 16 weeks were enrolled. Subjects were excluded if they were participating in any other clinical trial, had an acute disease, had a history of allergic reaction to any of the vaccine components, were undergoing immunosuppressive therapy, had received any immunoglobulin therapy or blood products before the start of the trial or during the trial, or had been administered any vaccines or experimental drug or vaccine 30 days before the start of the trial or during the trial. Occurrence of any of the contracautionary or precautionary indications for pertussis vaccination after any dose of trial vaccines resulted in exclusion from the trial. 14 
Vaccines
Vaccines were administered as a primary vaccination course at 2, 3, and 4 months of age. A 0.5-mL dose of the candidate vaccine (DTaP-HBV-IPV) was composed of ≥30 IU (25 Lf) of diphtheria toxoid, ≥40 IU (10 Lf) of tetanus toxoid, 25 µg of adsorbed pertussis toxoid, 25 µg of adsorbed filamentous hemagglutinin, 8 µg of adsorbed pertactin, 10 µg of recombinant hepatitis surface B antigen; 40 D-antigen units of type 1 (Mahoney), 8 D-antigen units of type 2 (MEF-1) and 32 D-antigen units of type 3 (Saukett) of the polio virus, and 0.7 mg of aluminum salts (hydroxide and phosphate). The conjugate Hib vaccine was supplied as a lyophilized pellet containing 10 µg of polyribose-ribitolphosphate conjugated to ~30 µg of tetanus toxoid, 0.12 mg of aluminum phosphate, and 10 mg of lactose. The mixed administration (DTaP-HBV-IPV/Hib) was prepared by reconstituting the lyophilized Hib vaccine pellet with liquid DTaP-HBV-IPV vaccine. For separate concomitant administration (DTaP-HBV-IPV + Hib), the Hib vaccine was resuspended in 0.5 mL of saline solution diluent (9 mg NaCl/mL) as supplied by the manufacturer. All vaccines were administered by deep intramuscular injection into the anterolateral thigh. Single lots of DTaP-HBV-IPV and Hib vaccine were used. 
Immunogenicity Analysis
Blood samples were taken immediately before the first dose and 21 to 42 days after the final dose and stored at <-20°C until analysis was conducted at SmithKline Beecham Biologicals laboratories in a blinded fashion. Antibodies against diphtheria, tetanus, pertussis antigens (PT, filamentous hemagglutinin, and PRN), and polioviruses were measured by standard techniques as described before. 10, 15 An enzymelinked immunosorbent assay was used to measure the anti-PRP antibodies elicited by the Hib vaccine. All antibody concentrations except for B. pertussis at or above the assay cutoffs were considered to correlate with protection, because there is no generally accepted, well-defined antibody concentration to single antigens that correlates with protection. Therefore a vaccine response was defined as in previous studies. 16, 17 Reverse cumulative distribution curves have been used to compare antibody concentrations between trials. 18 Reverse cumulative distribution curves for all 3 anti-pertussis antibody concentrations induced by either the mixed or separate vaccine administration were compared with the immunogenicity data from an earlier efficacy in which the same DTaP component (Infanrix) as used here was shown to have an efficacy of 88.7% (95% CI 76.6 to 94.6). 19 In this efficacy trial all lots provided a similar degree of protection. We used the data from the lots from the efficacy trial that induced the highest (DTaP101A2) and lowest (DTaP117B2) antibody titers for comparison with the data from this study.
Reactogenicity Analysis
Diary cards were used by parents or guardians to solicit local reactions (pain, redness, and swelling) and general adverse experiences (fever, fussiness, vomiting, diarrhea, loss of appetite, restlessness, sleepiness) on the day of vaccination and for 3 subsequent days. Symptoms were graded from 1 to 3 in intensity. Total incidences and grade 3 are reported. Fever was defined as rectal body temperature ≥38.0°C and grade 3 fever as a temperature ≥39.5°C. Grade 3 pain was defined as being present if a child cried when his or her limb was moved. Redness or swelling at the injection site >20 mm was defined as grade 3. Grade 3 fussiness was defined as inconsolable, persistent crying. For all other symptoms grade 3 was defined as preventing normal daily activities.
Statistical Analysis
The primary objective of this study was to demonstrate that no decrease occurred in responses to the mixed administration (DTaP-HBV-IPV/Hib compared with separate administration
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(DTaP-HBV-IPV + Hib) (ie, demonstrate clinical noninferiority) according to the guidelines described elsewhere. 20 The noninferiority of the mixed administration compared with that of the separate administration with respect to the seroprotection/vaccine response rates and postvaccination GMTs/GMCs was defined by the upper limit of the 90% CI of the difference in seroprotection/vaccine response rates (separatemixed) or GMT/GMC ratio (separate/ mixed) being below the prespecified (a priori) limit defining clinical noninferiority. The a priori limit was set at a 10% decrease in the percent of subjects with anti-PRP titer ≥1 µg/mL (primary end point), the D, T, HBV, IPV seroprotection rates, and the pertussis vaccine response rates (secondary end points). For the percent of subjects with anti-PRP titer ≥0.15 µg/mL, a 5% decrease was set as the a priori limit (secondary end point). A decrease in the pertussis GMT/GMC ratio was set at 1.5 (secondary end point). The 90% CI for the vaccine differences in seroprotection/vaccine response rate was obtained from StatXact 3.0, whereas the CI for the GMT/GMC ratio was derived from a 1-way analysis of variance model on the log-transformed antibody titers. The 95% CIs were calculated for all seroprotection, pertussis vaccine response rates, postvaccination GMTs/GMCs, and the percentage of subjects having adverse reactions (descriptive analysis). N, Number of subjects with available results; n, number of subjects with seroprotective concentrations; s, separate administration; m, mixed administration; ∆SP, difference in seroprotection rates (separate -mixed). *The mixed administration was statistically less immunogenic (ie, the upper limit of 90% CI fell outside the a priori limit of clinical noninferiority). † Secondary end point. ‡ Primary end point. Table I . Anti-PRP seroprotection rates and GMCs 1 month after vaccination VOLUME 137, NUMBER 3 out because of a protocol violation (separate group). No subjects dropped out as a result of an adverse event.
Immunogenicity
Subjects were eligible for the immunogenicity analysis if a postvaccination sample had been taken and they had complied with the criteria specified in the protocol (the according to protocol analysis). A total of 73 subjects were eliminated from the immunogenicity analysis: 35 from the mixed group and 38 from the separate group. One subject was lost to follow-up after the first dose, and therefore no blood sample was taken (this was the only subject eliminated
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RESULTS
Of the 359 subjects enrolled, only 10 failed to complete the study; 8 were lost to follow-up: 5 from the mixed group (DTaP-HBV-IPV/Hib) and 3 from the separate group (DTaP-HBV-IPV + Hib), 1 migrated from the study area (mixed group), and another dropped N, Number of subjects with available results; n, number of subjects showing a VR; VR, appearance of antibodies above the assay cutoff (5 EL.U/mL) in initially seronegative subjects and at least maintenance of prevaccination antibody titers in initially seropositive; s, separate administration; m, mixed administration; ∆ VR, difference in VR rates (separate -mixed). Ratio GMTs † : s/m (90% CL) -anti-PT: 1.10 (0.9-1.2); anti-FHA: 1.02 (0.9-1.2); anti-PRN: 1.06 (0.9-1.2). *The mixed administration was statistically less immunogenic (ie, the upper limit of 90% CI fell outside the a priori limit of clinical noninferiority). † Secondary end point. N, Number of subjects with available results; n, number of subjects with seroprotective antibody titers/concentrations; s, separate administration; m, mixed administration; ∆ SP, difference in seroprotection rates (separate -mixed). *The mixed administration was statistically less immunogenic (ie, the upper limit of 90% CI fell outside the a priori limit of clinical noninferiority). † Secondary end point. Table III . Anti-diphtheria, anti-tetanus, and anti-hepatitis B surface seroprotection rates and GMCs, and anti-polio seroprotection and GMTs 1 month after vaccination from the ATP reactogenicity analysis because no diary card was returned). Five subjects were above the age limit specified in the protocol, 37 and 27 subjects failed to comply with vaccination and blood sampling schedules, respectively, and a further 3 failed to provide postvaccination blood samples. The results of the ATP analyses are presented in Tables I, II, and III. A reanalysis of all subjects from whom data had been collected (intention-to-treat analysis) indicated that no bias was introduced by focusing on the ATP population (data not shown).
RESPONSE TO HIB ANTIGEN (TABLE I).
After vaccination all subjects except 1 infant in the mixed group had anti-PRP titers ≥0.15 µg/mL. A total of 77.2% and 88.6% in the mixed and separate groups, respectively, also had antibody concentrations ≥1 µg/mL. After vaccination the GMCs were 2.62 µg/mL (95% CI 2.1 to 3.2) and 4.45 µg/mL (95% CI 3.6 to 5.5) in the mixed and separate groups, respectively. With the specifically predefined criteria, statistical noninferiority of the mixed administration compared with the separate administration could not be established. The difference in the percentage of subjects with seroprotective concentrations (≥0.15 µg/mL) between the groups was only 0.69%; however, the upper limit of the 90% CI (5.3%) fell marginally outside the a priori limit (5%).
RESPONSE TO PERTUSSIS ANTIGENS (TABLE II).
The mixed administration was shown to be at least as immunogenic as the separate administration with respect to the vaccine response rates and postvaccination GMCs against all 3 pertussis antigens (secondary end points). The Figure shows the comparison of the anti-pertussis reverse cumulative distribution curve derived from subjects (both groups) in this study with historical data from subjects in an earlier efficacy trial who
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Figure. had received the licensed DTaP (Infanrix) vaccine. 20 The pertussis response induced in subjects receiving the mixed and separate administrations of the candidate and Hb vaccines in this trial was comparable to that seen in subjects receiving DTaP in the earlier efficacy trial. (TABLE III) . One month after the third dose was administered, all subjects had seroprotective antibody concentrations against diphtheria, tetanus toxoids, and polio virus types 1 and 3. One subject, who was in the mixed group, failed to produce protective titers against polio virus type 2. A total of 98.6% of subjects in both groups had seroprotective anti-hepatitis B surface titers. With respect to the seroprotection rates (secondary end points), the mixed administration was not inferior to the separate administration. In addi-309 tion, no relevant differences in postvaccination GMC/GMTs were observed. Table IV shows the incidence of local and general symptoms solicited. For the total incidence calculation, a local reaction was counted once, even if it was recorded at both sites (for the separate administration); no difference between vaccine administrations was noted. If both sites are considered, the Table V . Incidence (%) of local symptoms and fever per subject at each dose overall incidence was lower after the mixed administration (1 site). Local reactions at the injection site of the 6-component vaccine were similar to those observed at the injection site of the 5-component vaccine. A similar incidence in systemic reactions, fever (≥38°C), fussiness, restlessness, and sleepiness was reported for both groups (Table IV) . This was also true for diarrhea, loss of appetite, and vomiting (data not shown). Most systemic reactions occurred within the first 2 days of vaccination and were mild and self-limiting. The incidence of pain decreased with each successive dose, whereas swelling and redness increased somewhat, except for redness with the third dose of separate administration (Table  V) . The incidence of fever decreased with each successive dose after the separate administration; with mixed administration it was highest with the second dose.
RESPONSES TO DIPHTHERIA AND TETANUS TOXOIDS, HEPATITIS B SUR-FACE ANTIGEN, AND POLIO ANTIGENS
Reactogenicity
Reports of unsolicited symptoms were received after 472 doses; only 13 were considered to be related to vaccination (9 and 4 in the mixed and separate groups, respectively). Four of these reports were related to local reactions, which extended past the 4-day follow-up period, and 9 were general systemic reactions. However, all resolved uneventfully. A total of 8 serious adverse events occurred, 7 of which were judged to be unrelated to vaccination. One SAE (pneumonia, gastroenteritis, and respiratory obstruction) was reported as "unlikely to be related to vaccination" by the study physician. There was no report of hypotonic hyporesponsiveness episodes or of seizures.
DISCUSSION
This trial was designed to investigate the feasibility of giving the Hib conjugate vaccine either as a mixed or as a separate concomitant administration with a DTaP-HBV-IPV vaccine. Both the mixed and the separate administrations were immunogenic in the vast majority of subjects inducing seroprotective postvaccination antibody concentrations against diphtheria, tetanus, hepatitis B, and polioviruses, and Hib titers ≥0.15 µg/mL. An equivalently high pertussis vaccine response was seen between groups. In addition, the vaccines were well tolerated, with an obvious reduction in the total number of injection site reactions when given as a mixed administration.
However, consistent with our earlier observation 21 and those of others since, [8] [9] [10] [22] [23] [24] [25] the mixed administration elicited a lower anti-PRP response than the separate administration. The question arises as to whether the lower immunogenicity may result in reduced protection against invasive Hib disease. In this study only 1 subject in the mixed group failed to elicit an anti-PRP-antibody response ≥0.15 µg/mL, and the GMCs reached in this group were similar to those reported for other DTaP-based/Hib vaccines 7, 10, 15, 24, 25 licensed in many European countries and even for monovalent Hib conjugate vaccines. [26] [27] [28] [29] In addition, the use of 0.15 µg/mL and 1 µg/mL as threshold of short and long-term protection to assess conjugate Hib vaccines or Hibbased combinations 30 is increasingly being questioned. 13 First, these serologic markers were based on the waning response after the administration of unconjugated plain polysaccharide vaccines, which crucially lack the ability to induce memory. 31 Second, if solely based on these values alone and especially the long-term marker, the concentrations induced by conjugate vaccines would not predict the protective efficacies seen in recent field trials. [26] [27] [28] Consequently, recent attention has focused on the importance of immunologic memory when the anti-PRP response after DTaP-based combinations is evaluated. The existence of a PRP-polysaccharide specific B-cell-memory has successfully been demonstrated after both combined and separate administration of Hib vaccines. 10 Other researchers have conclusively demonstrated the existence of immune memory in a number of ways, for example, by observing an anamnestic booster response that clearly exceeds levels reported in unprimed infants 11, 24, 25 or by the predominance of immunoglobulin G over immunoglobulin M antibodies after a booster thereby, indicating a true secondary type immune response. 22 Furthermore a number of studies also suggest that the functional activity of the anti-PRP antibodies is also not impaired by combination, as reviewed by Eskola et al. 13 Based on these considerations, DTaP/ Hib vaccines and DTaP-IPV/Hib vaccines were licensed in Germany at the end of 1996. Currently, approximately 90% of all DTaP vaccines are given as DTaP/Hib-based combinations, yet the number of invasive Hib cases continues to decline, and DTaP/Hib vaccine failures are exceedingly rare in fully immunized children. 12 Thus it is our overall conclusion that the somewhat lower anti-PRP titers may be of less concern than originally thought.
Of note, a high degree of seroprotection against diphtheria, tetanus, hepatitis B, and the 3 polioviruses was seen in both study groups. Furthermore with respect to the end points mentioned previously, the mixed administration was found not to be less immunogenic than the separate administration. Serologic markers for protection against pertussis, however, are not well defined. Although 2 recent studies have independently associated antibodies against PRN, fimbriae, and PT as serologic markers of protection for acellular pertussis vaccines, definite serologic correlates of protection for all vaccines have not yet been established. 32, 33 Nevertheless, study participants in this trial had equivalent anti-PT, anti-filamentous hemagglutinin, and anti-PRN concentrations to those observed in subjects in an earlier DTaP efficacy trial, in which protection from pertussis defined by the World Health Organization was shown to be 88.7%. 19 The DTaP vaccine used in this efficacy trial was identical to the DTaP component of the candidate DTaP-HBV-IPV in this investigation. Additional efficacy trials with DTaP-based combination vaccines are no longer feasible, and in this situation it is reasonable to assume that a similar immunogenicity will result in a similar rate of protection.
The incidence of severe reactions was similar to that reported for DTaP vaccines. 6, 16, 34 In addition, the inclusion of the Hib component to the DTaP-HBV-IPV vaccine in the mixed administration did not result in any further increase in local reactions over the incidence observed at the DTaP-HBV-IPV site (separate administration). In 2 earlier reports 16, 34 swelling and redness increased with successive doses; however, in this study this tendency was less marked. In terms of general symptoms, the vaccines administered to both study groups were similarly well tolerated, and no increase in fever occurred with successive doses.
Recent years have shown an increasing number of antigens to be added to the list of vaccines to protect children. Combination vaccines are urgently needed to attain high levels of vaccine coverage. Both administrations of the candidate vaccine investigated in this feasibility trial may contribute to the achievement of this goal.
